Nanoparticulate MgH 2 suppresses TRPM2-mediated NLRP3 inflammasome to relieve bone cancer pain
Molecular Pain · 2025
DOI: 10.1177/17448069251348770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2025. Verfasst von Hang Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: TRPM Cation Channels, NLR Family, Pyrin Domain-Containing 3 Protein, Bone Neoplasms, Cancer Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Youth Cultivation Project of National Natural Science Fund.
Abstract (Originalsprache)
Background
Bone cancer metastases are the third most common site of cancer spread after lungs and liver. This condition often causes severe pain that impairs patients’ physical, psychological, and social well-being. We aimed to explore the potential therapeutic benefits of magnesium hydride (MgH 2 ) on bone cancer pain (BCP).
Methods
A BCP model was established in Wistar rats. Daily oral dosing of 0.5% w/w MgH 2 was administered. Assessment included pain sensitivity, motor coordination, and emotional behaviors. Hippocampal samples underwent RNA sequencing, Western blotting, immunofluorescence, and quantitative RT-PCR.
Results
MgH 2 markedly reduced mechanical hypersensitivity and depressive behaviors in rats with BCP. These effects were linked to suppression of the TRPM2–NLRP3 signaling axis in hippocampal microglia. Additionally, MgH 2 served as an adjuvant to reduce opioid tolerance during fentanyl co-treatment, enabling lower opioid dosages. Collectively, MgH 2 inhibited TRPM2 activation, microglial activation, oxidative stress, and NLRP3 inflammasome formation, which together reduced neuroinflammation and improved therapeutic outcomes.
Conclusion
MgH 2 nanoparticles may relieve BCP and comorbid depressive symptoms by inhibiting TRPM2-mediated NLRP3 inflammasome activation in hippocampal microglia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
- Department of Anesthesiology, Jiading District Central Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, China.
- Department of Naval Medicine, Naval Medical University, Shanghai, China.
- Institute of Neuroscience and Key Laboratory of Molecular Neurobiology of Military of Education, Naval Medical University, Shanghai, China.
- Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Feixiang Wu
Förderung
- Youth Cultivation Project of National Natural Science Fund
Zitieren
APA
Xu, H., Lu, H., Lu, L., Li, Z., Piao, Z., Jia, Y., Meng, X., & Wu, F. (2025). Nanoparticulate MgH 2 suppresses TRPM2-mediated NLRP3 inflammasome to relieve bone cancer pain. Molecular Pain. https://doi.org/10.1177/17448069251348770
Vancouver
Xu H, Lu H, Lu L, Li Z, Piao Z, Jia Y, et al. Nanoparticulate MgH 2 suppresses TRPM2-mediated NLRP3 inflammasome to relieve bone cancer pain. Molecular Pain. 2025. doi:10.1177/17448069251348770
BibTeX
@article{Xu2025,
author = {Xu, Hang and Lu, Hongtao and Lu, Lu and Li, Zhenghao and Piao, Zhisheng and Jia, Yi and Meng, Xiaoyan and Wu, Feixiang},
title = {Nanoparticulate MgH 2 suppresses TRPM2-mediated NLRP3 inflammasome to relieve bone cancer pain},
journal = {Molecular Pain},
year = {2025},
doi = {10.1177/17448069251348770}
}
EUVIMED